Sarah Gilbert

Last updated


Sarah Gilbert

DBE
Born
Sarah Catherine Gilbert

April 1962 (age 59)
Alma mater University of East Anglia (BSc)
University of Hull (PhD)
Known for Vaccinology
Children3
Awards Albert Medal (2021)
Princess of Asturias Award (2021)
Scientific career
Fields Vaccines [1]
Institutions University of Oxford
Vaccitech
Delta Biotechnology
Leicester Biocentre
Brewing Industry Research Foundation
Thesis Studies on lipid accumulation and genetics of Rhodosporidium toruloides  (1986)
Doctoral advisor Colin Ratledge, Dr M. Keenan
Website www.jenner.ac.uk/team/sarah-gilbert OOjs UI icon edit-ltr-progressive.svg

Dame Sarah Catherine Gilbert DBE (born April 1962) is a British vaccinologist who is Saïd Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. [2] [3] [4] [5] [6] Gilbert specialises in the development of vaccines against influenza and emerging viral pathogens. [7] She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011. On New Year's Day 2020 Gilbert read on ProMED-mail about four people in China suffering from a strange pneumonia of unknown cause, in Wuhan, China. [8] Within two weeks a vaccine had been designed at Oxford against the new pathogen. [9] On 30 December 2020, the Oxford–AstraZeneca COVID-19 vaccine she co-developed with the Oxford Vaccine Group was approved for use in the United Kingdom. [10] As of 2021 more than 1.5 billion doses of the vaccine have been released [11] to more than 170 countries worldwide. [12]

Contents

Early life and education

Gilbert was born in Kettering, Northamptonshire. Her father was an office manager for a shoemakers and her mother was a primary school teacher. [13] Gilbert attended Kettering High School for Girls, where she realised that she wanted to work in medicine. [14] [15] She obtained nine O-Levels with six A grades. [14] She graduated with a Bachelor of Science degree in biological sciences from the University of East Anglia (UEA) in 1983. [16] While at UEA she began playing the saxophone, which she would practise in the woods around the UEA Broad so as not to disturb others in her halls. [14] [17] She moved to the University of Hull for her doctoral degree, where she investigated the genetics and biochemistry of the yeast Rhodosporidium toruloides , graduating with a PhD in 1986. [18] [15]

Research and career

After earning her doctoral degree Gilbert worked as a postdoctoral researcher in industry at the Brewing Industry Research Foundation before moving to the Leicester Biocentre. In 1990, Gilbert joined Delta Biotechnology, a biopharmaceutical company that manufactured drugs in Nottingham. [15] [19] In 1994, Gilbert returned to academia, joining the laboratory of Adrian V. S. Hill. Her early research considered host–parasite interactions in malaria. [15] She became a University lecturer in 1999 and she was made a Reader in Vaccinology at the University of Oxford in 2004. [15] She was made Professor at the Jenner Institute in 2010. With the support of the Wellcome Trust, Gilbert started work on the design and creation of novel influenza vaccinations. [15] In particular, her research considers the development and preclinical testing of viral vaccinations, which embed a pathogenic protein inside a safe virus. [20] [21] These viral vaccinations induce a T cell response, which can be used against viral diseases, malaria and cancer. [20]

Graphical representation of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), created by the Centers for Disease Control and Prevention, which reveals ultrastructural morphology exhibited by coronaviruses. SARS-CoV-2 without background.png
Graphical representation of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), created by the Centers for Disease Control and Prevention, which reveals ultrastructural morphology exhibited by coronaviruses.

Gilbert was involved with the development and testing of the universal flu vaccine. Unlike conventional vaccinations, the universal flu vaccine did not stimulate the production of antibodies, but instead triggers the immune system to create T cells that are specific for influenza. [22] It makes use of one of the core proteins (nucleoprotein and matrix protein 1) inside the Influenza A virus, not the external proteins that exist on the outside coat. [23] As the immune system weakens with age, conventional vaccinations are not effective for elderly. The universal flu vaccine does not need to be reformatted every year and stops people from needing a seasonal flu vaccine. [23] Her first clinical trials, which were in 2008, made use of the Influenza A virus subtype H3N2, and included daily monitoring of the patient's symptoms. [23] [24] It was the first study that it was possible to stimulate T cells in response to a flu virus, and that this stimulation would protect people from getting the flu. [23] Her research has demonstrated that the adenoviral vector ChAdOx1 can be used to make vaccinations that are protective against Middle East respiratory syndrome (MERS) in mice and able to induce immune response against MERS in humans. [25] [26] The same vector was also used to create a vaccine against Nipah which was effective in hamsters (but never proven in humans), [27] in addition to a potential vaccine for Rift Valley Fever that was protective in sheep, goats, and cattle (but not proven in humans). [28]

Gilbert has been involved with the development of a new vaccination to protect against coronavirus since the beginning of the COVID-19 pandemic. [29] [30] [31] [2] She leads the work on this vaccine candidate alongside Andrew Pollard, Teresa Lambe, Sandy Douglas, Catherine Green and Adrian Hill. [32] As with her earlier work, the COVID-19 vaccine makes use of an adenoviral vector, which stimulates an immune response against the coronavirus spike protein. [29] [30] Plans were announced to start animal studies in March 2020, and recruitment began of 510 human participants for a phase I/II trial on 27 March. [33] [34] [35] In April 2020, Gilbert was interviewed about the developments by Andrew Marr on BBC television. [36] That same month, Gilbert was reported as saying that her candidate vaccine could be available by September 2020, [37] if everything goes to plan with the clinical trial, which has received funding from sources such as the Coalition for Epidemic Preparedness Innovations. [38] Gilbert delivered an update in September 2020 that the vaccine, AZD1222, was being produced by AstraZeneca while phase III trials were ongoing. [39] Because of her vaccine research, Gilbert featured on The Times ' 'Science Power List' in May 2020. [40]

Recognition

Gilbert was the subject of BBC Radio 4's The Life Scientific in September 2020. [41] She was also on the list of the BBC's 100 Women announced on 23 November 2020, [42] and became a senior associated research fellow at Christ Church, Oxford. [43] Gilbert was awarded the Rosalind Franklin medal for her services to science by Humanists UK at its annual Rosalind Franklin Lecture on 5 March 2021, at which she delivered a lecture titled ‘Racing against the virus’. The lecture detailed the history of the science of vaccination and recounted the progress of the Oxford/AstraZeneca vaccine. [44]

In June 2021, Gilbert received a standing ovation at the 2021 Wimbledon Championships. [45] In 2021 Gilbert had a Barbie doll made in her honour by the toy manufacturer Mattel. [46] [47]

Awards

Personal life

Gilbert gave birth to triplets in 1998. Her partner gave up his career to be their primary parent. [15] All of the triplets are now studying biochemistry at university. [13]

Selected publications

Gilbert has an h-index of 92 according to Google Scholar. [1] Her publications include: [53] [54]

Related Research Articles

Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company. It is the world's largest manufacturer of vaccines located in the city of Pune, India and was founded by Cyrus Poonawalla in 1966. The company is a subsidiary of the holding company 'Cyrus Poonawalla Group'.

Oxford Vaccine Group Research group of the University of Oxford

The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford. It was founded in 1994 by Professor E. Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England. The group, led by Professor Andrew Pollard since 2001, comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students.

Adrian Vivian Sinton Hill, is an Irish vaccinologist, Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

COVID-19 pandemic in Panama Ongoing COVID-19 viral pandemic in Panama

The COVID-19 pandemic in Panama is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Panama on 9 March 2020. One of the dead was a 64-year-old male, who also suffered from complications of diabetes and pneumonia. Of those infected, 83 were admitted to hospital. The infected individuals belong to the 29-59 age group and had each recently travelled abroad. A 13-year-old girl died of COVID-19 on 23 March.

Trudie Lang is a Professor of Global Health Research at the University of Oxford. She specialises in clinical trials research capacity building in low-resource setting, and helped to organise the trial for the drug brincidofovir during the 2014 Ebola virus outbreak.

Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a Professor of Virology at the Amsterdam University Medical Center of the University of Amsterdam. She has been involved in the development of Janssen's Ebola vaccine and is involved in the development of a universal flu vaccine, HIV vaccine, RSV vaccine and COVID-19 vaccine.

Kizzmekia Corbett American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is the Shutzer Assistant Professor at the Harvard Radcliffe Institute and assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. She joined Harvard following six years at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, National Institutes of Health based in Bethesda, Maryland. She earned a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill in 2014. Appointed to the VRC in 2014, Corbett was the scientific lead of the VRC's Coronavirus Team, with research efforts aimed at propelling novel coronavirus vaccines, including a COVID-19 vaccine. In February 2021, Corbett was highlighted in the Time's "Time100 Next" list under the category of Innovators, with a profile written by Anthony Fauci.

Jenner Institute Vaccine research institute in Oxford

The Jenner Institute is a research institute on the Old Road Campus in Headington, east Oxford, England. It was formed in November 2005 through a partnership between the University of Oxford and the UK Institute for Animal Health. It is associated with the Nuffield Department of Medicine, in the Medical Sciences Division of Oxford University. The institute receives charitable support from the Jenner Vaccine Foundation.

Catherine Mary Green is an English biologist who is an Associate Professor in Chromosome Dynamics at the Wellcome Centre for Human Genetics at the University of Oxford. Her research considers chromosome stability during the replication of DNA. During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine.

Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

The Vaccine Taskforce in the United Kingdom of Great Britain and Northern Ireland was set up in April 2020 by the Second Johnson ministry, in collaboration with Chief Scientific Advisor Patrick Vallance and Chief Medical Officer Professor Chris Whitty, in order to facilitate the path towards the introduction of a COVID-19 vaccine in the UK and its global distribution. The taskforce acts to coordinate the research efforts of government with industry, academics and funding agencies in order to be able to make timely decisions which expedite vaccine development and deployment.

ChAdOx1 is an adenoviral vector for vaccines that was developed by the Jenner Institute, University of Oxford. The vector is a chimpanzee adenovirus modified to avoid its replication.

COVID-19 vaccination in the United Kingdom Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom. The UK's vaccination rollout was the world's first mass immunisation programme for the disease when it began on 8 December 2020 after Margaret Keenan received her first dose of two. As of 6 October 2021, 49,068,705 first doses and 45,078,529 second doses of a vaccine had been administered across the UK.

Timeline of the COVID-19 pandemic in the United Kingdom (January–June 2021) Daily UK events related to the pandemic in 2021

The following is a timeline of the COVID-19 pandemic in the United Kingdom from January 2021 to June 2021.

Shabir Madhi South African physician and professor

Shabir Ahmed Madhi is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

COVID-19's caused virus, SARS-CoV-2, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

The World Doctors Alliance is an independent organisation of anti-vaccine and COVID-19 denial skeptics and conspiracy theorists which was established in May 2020 by Mohammad Iqbal Adil. The aim of the organisation is to challenge the opinion of the mainstream medical opinion of the COVID-19 pandemic. Claims made by the World Doctors Alliance have been universally rejected by the legitimate medical community and it is considered to be a source of misinformation regarding the COVID-19 pandemic.

COVID-19 vaccine misinformation and hesitancy Misinformation regarding the SARS-CoV-2 vaccine and the resulting hesitancy towards it

Anti-vaccination activists and other people in multiple countries have spread a variety of unfounded conspiracy theories about COVID-19 vaccines based on misunderstood science, religion, and other factors. Theories including overblown claims about side effects, a story about COVID-19 being spread by childhood vaccines, misrepresentations about how the immune system works, and when and how COVID-19 vaccines are made have proliferated, contributing to widespread vaccine hesitancy among the public. This has led to governments around the world introducing measures to encourage vaccination, which has in turn led to further misinformation about the legality and effect of these measures themselves.

United Kingdom responses to the COVID-19 pandemic Actions by the United Kingdom regarding the COVID-19 pandemic

The United Kingdom's response to the COVID-19 pandemic with consists of various measures by the national health services community; the British and devolved governments; the military; and the research sector.

References

  1. 1 2 Sarah Gilbert publications indexed by Google Scholar OOjs UI icon edit-ltr-progressive.svg
  2. 1 2 Lane, Richard (2020). "Sarah Gilbert: carving a path towards a COVID-19 vaccine". The Lancet . 395 (10232): 1247. doi:10.1016/S0140-6736(20)30796-0. PMC   7162644 . PMID   32305089.
  3. "Sarah Gilbert – Nuffield Department of Medicine". University of Oxford. Retrieved 10 February 2020.
  4. "Professor Sarah Gilbert". University of Oxford. Retrieved 10 February 2020.
  5. "Professor Sarah Gilbert | University of Oxford". University of Oxford. Retrieved 10 February 2020.
  6. "Our Team". vaccitech.co.uk. Retrieved 28 March 2020.
  7. "Professor Sarah Gilbert | Hic Vac". hic-vac.org.
  8. Gilbert, Sarah; Green, Catherine (2021). Vaxxers : the inside story of the Oxford vaccine and the race against the virus. London. ISBN   978-1529369854.
  9. "Centre Court ovations, limbo-dancing grans – it's all been humbling, say Oxford vaccine creators". The Guardian . Retrieved 9 July 2021.
  10. "Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK". BBC News. BBC. 30 December 2020. Retrieved 30 December 2020.
  11. "Prof Sarah Gilbert, Covid vaccine creator: Now let's take on 12 more diseases". BBC News . Retrieved 17 October 2021.
  12. "Oxford vaccine reaches one billion doses released". University of Oxford . Retrieved 12 September 2021.
  13. 1 2 Cookson, Clive (24 July 2020). "Sarah Gilbert, the researcher leading the race to a Covid-19 vaccine". Financial Times . Retrieved 25 June 2021.
  14. 1 2 3 "Coronavirus vaccine: Who is Professor Sarah Gilbert?". Newsround . Retrieved 28 June 2021.
  15. 1 2 3 4 5 6 7 Admin. "Professor Sarah Gilbert". Working for NDM. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  16. "The UEA graduate leading hunt for coronavirus vaccine". Eastern Daily Press . Retrieved 20 June 2021.
  17. "UEA alumni in 2020". University of East Anglia . Retrieved 28 June 2021.
  18. Gilbert, Sarah Catherine (1986). Studies on lipid accumulaltion and genetics of Rhodosporidium toruloides. jisc.ac.uk (PhD thesis). University of Hull. OCLC   499901226. EThOS   uk.bl.ethos.381881.
  19. "Vaccine matters: Can we cure coronavirus?". Science Magazine. 12 August 2020. Retrieved 7 September 2020.
  20. 1 2 "Sarah Gilbert: Viral Vectored Vaccines — Nuffield Department of Medicine". University of Oxford. Retrieved 27 March 2020.
  21. "Professor Sarah Gilbert | Hic Vac". hic-vac.org. Retrieved 27 March 2020.
  22. "World-First Trial for Universal Flu Vaccine". Splice. 11 October 2017. Retrieved 27 March 2020.
  23. 1 2 3 4 Jha, Alok; correspondent, science (6 February 2011). "Flu breakthrough promises a vaccine to kill all strains". The Guardian. ISSN   0261-3077 . Retrieved 27 March 2020.
  24. "Sarah Gilbert — The Jenner Institute". jenner.ac.uk. Retrieved 27 March 2020.
  25. Munster, Vincent J.; Wells, Daniel; Lambe, Teresa; Wright, Daniel; Fischer, Robert J.; Bushmaker, Trenton; Saturday, Greg; van Doremalen, Neeltje; Gilbert, Sarah C.; de Wit, Emmie; Warimwe, George M. (2017). "Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model". NPJ Vaccines. 2 (1): 28. doi:10.1038/s41541-017-0029-1. ISSN   2059-0105. PMC   5643297 . PMID   29263883.
  26. "New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia". www.vaccitech.co.uk. 20 December 2019. Retrieved 22 March 2021.
  27. Halstead, Scott B.; van Doremalen, Neeltje; Lambe, Teresa; Sebastian, Sarah; Bushmaker, Trenton; Fischer, Robert; Feldmann, Friederike; Haddock, Elaine; Letko, Michael; Avanzato, Victoria A.; Rissanen, Ilona; LaCasse, Rachel; Scott, Dana; Bowden, Thomas A.; Gilbert, Sarah; Munster, Vincent (2019). "A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters". PLOS Neglected Tropical Diseases. 13 (6): e0007462. doi:10.1371/journal.pntd.0007462. ISSN   1935-2735. PMC   6581282 . PMID   31170144.
  28. Warimwe, George M.; Gesharisha, Joseph; Carr, B. Veronica; Otieno, Simeon; Otingah, Kennedy; Wright, Danny; Charleston, Bryan; Okoth, Edward; Elena, Lopez-Gil; Lorenzo, Gema; Ayman, El-Behiry; Alharbi, Naif K.; Al-dubaib, Musaad A.; Brun, Alejandro; Gilbert, Sarah C.; Nene, Vishvanath; Hill, Adrian V. S. (2016). "Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever". Scientific Reports. 6 (1): 20617. Bibcode:2016NatSR...620617W. doi:10.1038/srep20617. ISSN   2045-2322. PMC   4742904 . PMID   26847478.
  29. 1 2 "Two groups of UK scientists in race to develop coronavirus vaccine". London Evening Standard. 7 February 2020. Retrieved 27 March 2020.
  30. 1 2 "Vaccine trials among recipients of £20 million coronavirus research investment". Government of the United Kingdom. Retrieved 27 March 2020.
  31. "Oxford team to begin novel coronavirus vaccine research | University of Oxford". University of Oxford. Retrieved 27 March 2020.
  32. "COVID-19 Vaccine Trials | COVID-19". covid19vaccinetrial.co.uk. Retrieved 11 April 2020.
  33. Sample, Ian (19 March 2020). "Trials to begin on Covid-19 vaccine in UK next month". The Guardian . ISSN   0261-3077 . Retrieved 27 March 2020.
  34. Robson, Steve (20 March 2020). "British scientists hope to start coronavirus vaccine trials next month". manchestereveningnews.co.uk. Retrieved 27 March 2020.
  35. "UK scientists enrol volunteers for coronavirus vaccine trial". The Guardian. 17 March 2020.
  36. "Prof Sarah Gilbert: Coronavirus vaccine trials to start within days". The Andrew Marr Show . UK. 19 April 2020. Retrieved 19 April 2020.
  37. hermesauto (11 April 2020). "Coronavirus vaccine could be ready in six months, says UK scientist". The Straits Times. Retrieved 11 April 2020.
  38. Stephanie Baker (30 March 2020). "How Top Scientists Are Racing to Beat the Coronavirus". Bloomberg News . Retrieved 11 April 2020.
  39. Lovett, Samuel (1 September 2020). "'You just get on with it': The Oxford professor carrying the world's hopes of a coronavirus vaccine". The Independent. Retrieved 8 September 2020.
  40. Franklin-Wallis, Oliver (23 May 2020). "From pandemics to cancer: the science power list". The Times. ISSN   0140-0460 . Retrieved 26 May 2020.
  41. Presenter: Jim Al-Khalili; Producer: Anna Buckley (15 September 2020). "Sarah Gilbert on developing a vaccine for Covid-19". The Life Scientific . BBC. BBC Radio 4 . Retrieved 15 September 2020.
  42. "BBC 100 Women 2020: Who is on the list this year?". BBC News. 23 November 2020. Retrieved 23 November 2020.
  43. "e-Matters 25th February 2021". www.chch.ox.ac.uk. Retrieved 9 September 2021.
  44. 1 2 "Vaccine creator Professor Sarah Gilbert delivers Rosalind Franklin Lecture to thousands". Humanists UK. Retrieved 8 March 2021.
  45. Duncan, Conrad (28 June 2021). "Wimbledon crowd gives standing ovation to Oxford Covid vaccine developer". The Independent. Retrieved 29 June 2021.
  46. "Vaccinologist Barbie: Prof Sarah Gilbert honoured with a doll". the Guardian. 4 August 2021.
  47. Ross, Deborah. "Your Sarah Gilbert doll isn't realistic, Mattel. I want a Pay Gap Barbie" via www.thetimes.co.uk.
  48. Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal www.ox.ac.uk, Accessed 23 March 2021
  49. "No. 63377". The London Gazette (Supplement). 12 June 2021. p. B8.
  50. IT, Developed with webControl CMS by Intermark. "Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi and Sarah Gilbert - Laureates - Princess of Asturias Awards". The Princess of Asturias Foundation.
  51. "Royal Society of Medicine welcomes new Honorary Fellows and medal winners". Royal Society of Medicine . Retrieved 30 August 2021.
  52. "Covid vaccine co-creator Sarah Gilbert among 2022 UEA honorary graduates". Eastern Daily Press . Retrieved 30 August 2021.
  53. Sarah Gilbert publications from Europe PubMed Central
  54. Publications by Sarah Gilbert at ResearchGate OOjs UI icon edit-ltr-progressive.svg